Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Vietnam anti-odor insole OEM service

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.China graphene product OEM service

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Innovative insole ODM solutions in China

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.ODM pillow factory in China

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Indonesia OEM/ODM hybrid insole services

The LSD algorithm spotlights actively responding lung cells (green). Credit: Matthias Schmitt, Gargiulo Lab, Max Delbrück Center A new computer program allows scientists to design synthetic DNA segments that indicate, in real time, the state of cells. Reported by the Gargiulo lab in Nature Communications, it will be used to screen for anti-cancer or viral infections drugs, or to improve gene and cell-based immunotherapies. All the cells in our body have the same genetic code, and yet they can differ in their identities, functions, and disease states. Telling one cell apart from another in a simple manner, in real time, would prove invaluable for scientists trying to understand inflammation, infections or cancers. Now, scientists at the Max Delbrück Center have created an algorithm that can design such tools that reveal the identity and state of cells using segments of DNA called “synthetic locus control regions” (sLCRs). They can be used in a variety of biological systems. The findings, by the lab of Dr. Gaetano Gargiulo, head of the Molecular Oncology Lab, are reported in Nature Communications. “This algorithm enables us to create precise DNA tools for marking and studying cells, offering new insights into cellular behaviors,” says Gargiulo, senior author of the study. “We hope this research opens doors to a more straightforward and scalable way of understanding and manipulating cells.” This effort began when Dr. Carlos Company, a former graduate student at the Gargiulo lab and co-first author of the study, started to invest energy into making the design of the DNA tools automated and accessible to other scientists. He coded an algorithm that can generate tools to understand basic cellular processes as well as disease processes such as cancers, inflammation, and infections. “This tool allows researchers to examine the way cells transform from one type to another. It is particularly innovative because it compiles all the crucial instructions that direct these changes into a simple synthetic DNA sequence. In turn, this simplifies studying complex cellular behaviors in important areas like cancer research and human development,” says Company. Algorithm to make a tailored DNA tool The computer program is named “logical design of synthetic cis-regulatory DNA” (LSD). The researchers input the known genes and transcription factors associated with the specific cell states they want to study, and the program uses this to identify DNA segments (promoters and enhancers) controlling the activity in the cell of interest. This information is sufficient to discover functional sequences, and scientists do not have to know the precise genetic or molecular reason behind a cell’s behavior; they just have to construct the sLCR. The program looks within the genomes of either humans or mouse to find places where transcription factors are highly likely to bind, says Yuliia Dramaretska, a graduate student at the Gargiulo lab and co-first author. It spits out a list of 150-basepair long sequences that are relevant, and which likely act as the active promoters and enhancers for the condition being studied. “It’s not giving a random list of those regions, obviously,” she says. “The algorithm is actually ranking them and finding the segments that will most efficiently represent the phenotype you want to study.” Like a lamp inside the cells Scientists can then make a tool, called a “synthetic locus control region” (sLCR), which includes the generated sequence followed by a DNA segment encoding a fluorescent protein. “The sLCRs are like an automated lamp that you can put inside of the cells. This lamp switches on only under the conditions you want to study,” says Dr. Michela Serresi, a researcher at the Gargiulo lab and co-first author. The color of the “lamp” can be varied to match different states of interest, so that scientists can look under a fluorescence microscope and immediately know the state of each cell from its color. “We can follow with our eyes the color in a petri dish when we give a treatment,” Serresi says. The scientists have validated the utility of the computer program by using it to screen for drugs in SARS-CoV-2 infected cells, as published last year in “Science Advances.” They also used it to find mechanisms implicated in brain cancers called glioblastomas, where no single treatment works. “In order to find treatment combinations that work for specific cell states in glioblastomas, you not only need to understand what defines these cell states, but you also need to see them as they arise,” says Dr. Matthias Jürgen Schmitt, the researcher at the Gargiulo lab and co-first author, who used the tools in the lab to showcase their value. Now, imagine immune cells engineered in the lab as a gene therapy to kill a type of cancer. When infused into the patient, not all these cells will work as intended. Some will be potent and while others may be in a dysfunctional state. Funded by an European Research Council grant, the Gargiulo lab will be using this system to study the behavior of these delicate anti-cancer cell-based therapeutics during manufacturing. “With the right collaborations, this method holds potential for advancing treatments in areas like cancer, viral infections, and immunotherapies,” Gargiulo says. Reference: “Logical design of synthetic cis-regulatory DNA for genetic tracing of cell identities and state changes” by Carlos Company, Matthias Jürgen Schmitt, Yuliia Dramaretska, Michela Serresi, Sonia Kertalli, Ben Jiang, Jiang-An Yin, Adriano Aguzzi, Iros Barozzi and Gaetano Gargiulo, 5 February 2024, Nature Communications. DOI: 10.1038/s41467-024-45069-6

Understanding the connections between different brain regions could lead to better treatment options for conditions like Alzheimer’s, schizophrenia, and depression. In 2019, a technique known as BARseq was developed to map these connections by identifying brain cells through the genes they express and tracing their neural circuitry. Initially capable of mapping thousands of pathways using RNA “barcodes,” this technique has now been enhanced to map millions of neurons. The research has expanded into the visual cortex, investigating how brain function changes when neural pathways are disrupted, providing deeper insights into brain development and functioning. Researchers developed and enhanced BARseq, a technique to map brain cell connections by gene expression, aiming to improve treatments for neurological conditions. They discovered that blindness alters visual cortex gene expression, and ongoing work seeks to expand BARseq’s capabilities to understand brain connectivity and development. Exploring how different areas of the brain interact could lead to improved treatments for conditions such as Alzheimer’s, schizophrenia, and depression. In 2019, as a postdoc in Cold Spring Harbor Laboratory’s (CSHL’s) Zador lab, Xiaoyin Chen helped develop a technique to map these connections. BARseq identifies cells in the brain by the genes they use and traces the connecting neural circuitry. Early versions of BARseq mapped gene expression across thousands of neural pathways, using “barcodes” or short snippets of RNA. “I think of BARseq’s maps as sort of like a painting aid,” says former CSHL postdoc Xiaoyin Chen. “All these little dots make up shapes. And you can actually zoom in and look at different parts and distinguish different cell types.” Credit: Chen lab/Allen Institute for Brain Science Chen is now an assistant investigator at the Allen Brain Institute. He recently reunited with CSHL Professor Anthony Zador to upgrade BARseq’s capabilities. What does that look like? Instead of thousands of neurons, BARseq can now map millions. “We are focused on pushing BARseq forward. We want to make this easy for everybody to use, faster, more sensitive. Can we read out more information with it? With a much higher scale, you can start to answer different questions,” says Chen. Research on Visual Cortex Using BARseq The team began their search for answers in the brain’s visual cortex. Sight is one of the most common ways humans perceive the world. Information travels from the eyes to the visual cortex for processing. But what happens in the brain when the visual cortex’s neural inroads are cut or don’t form at all? “People have known for a while that visual inputs are very important in shaping the brain,” Chen explains. “But we don’t know, at the exact cell-type resolution BARseq provides, what actually happens.” Left: Each colored dot in this image of the brain’s outer layer, or cortex, is an individual gene. Right: Using BARseq, scientists can see how genes are clustered and identify the corresponding neurons, the larger colored dots seen here. Credit: Chen lab/Allen Institute for Brain Science The team used BARseq to map the brains of nine mice and traced gene expression in each mouse’s visual cortex. It’s the first time the technique has been used to map this many entire brains. Amazingly, the team found that if the mice went blind, the genes in the visual cortex started to look like those in neighboring cortical areas of the brain. “The effects of losing vision were very broad,” Chen explains. “The visual cortex itself changes. It becomes more similar to the areas around it. There are still a lot of questions about how development controls this patterning.” Chen is now working to expand BARseq’s capabilities even further. He and his team are using the technique to investigate how connections are wired in developing brains and how these connections evolve. “Understanding how cortical areas are set up is the first step in understanding these connections,” he says. “But it’s not enough. We still need to discover how they progress during development. BARseq can bring us closer to that goal.” Reference: “Whole-cortex in situ sequencing reveals input-dependent area identity” by Xiaoyin Chen, Stephan Fischer, Mara C. P. Rue, Aixin Zhang, Didhiti Mukherjee, Patrick O. Kanold, Jesse Gillis and Anthony M. Zador, 24 April 2024, Nature. DOI: 10.1038/s41586-024-07221-6

An agar plate with the human pathogen Pseudomonas aeruginosa (green) and three antibiotics (labeled A, B and C). Credit: Roderich Roemhild Understanding resistance rates and cross-resistance can improve the potency of sequential antibiotic treatment protocols. Sequential treatment using antibiotics that are similar but swapped around frequently is an effective way to kill bacteria and prevent drug resistance, a study in eLife reports. The results challenge a broad assumption that using similar antibiotics promotes cross-resistance to drugs, and show that available antibiotics could offer unexplored, highly potent treatment options. “We are currently in an antibiotic crisis, where the overuse of antibiotics is leading to increased antibiotic resistance and certain infections have become difficult and even impossible to treat,” says first author Aditi Batra, a graduate student at the Max Planck Institute for Evolutionary Biology and the University of Kiel, Germany. “It is the ability of pathogens to evolve and adapt to drugs that underlies this resistance, but evolutionary theory predicts that adaptation is difficult when the environment changes rapidly. We wanted to test if we could use sequential antibiotic treatment to slow down the evolution of human pathogens and limit drug resistance.” The team used bacteria called Pseudomonas aeruginosa (P. aeruginosa), which can cause pneumonia and other infections in humans. They tested three different sequences of antibiotics under laboratory conditions and measured their potency at killing off different sub-populations of evolved bacterial cells. Two sets of antibiotics belonged to a class of drugs called ß-lactams, which have a common structural component – a ß-lactam ring. The other set of antibiotics all worked by different mechanisms. To the team’s surprise, treatment with both sets of ß-lactam antibiotics was better at killing off bacterial populations than some of the unrelated antibiotics. Moreover, switching rapidly between the individual antibiotics produced much better extinction of bacterial populations than when the switch between antibiotics was slower. This suggests that fast switching between antibiotics constrained the bacteria’s ability to adapt to the drugs. Given this unexpected result, the team explored the mechanisms that cause this evolutionary constraint. They studied the changes in growth, resistance profiles and whole genome sequences of the P. aeruginosa populations treated with the most potent sequence of ß-lactam antibiotics, which combined carbenicillin, doripenem and cefsulodin. They noted that when the sequences were switched quickly, bacterial growth during a switch to doripenem was much lower than for the other two antibiotics, indicating that resistance to this drug might emerge more slowly. They also looked at whether physiological changes that occur as a result of drug treatment made the bacteria resistant or more susceptible to the other drugs in the sequence. They found that spontaneous development of resistance was much lower for doripenem than the other two drugs. There was also less cross-resistance towards this drug than the other two antibiotics. This lack of cross-resistance may indicate the presence of so-called collateral sensitivity; this means that the mutant cells, which have become resistant to one drug, maintain at least ancestral levels of susceptibility against the second drug. Collateral sensitivity is known to be important for the effectiveness of sequential treatment. “Although sequential treatments with such similar antibiotics should have sped up resistance evolution, we found this is not the case if resistance to one of the antibiotics cannot emerge easily, and if the antibiotics show collateral sensitivity to each other,” says senior author Hinrich Schulenburg, Fellow of the Max Planck Institute for Evolutionary Biology and Professor at the University of Kiel. “It is ironic that the differential cross-resistance profile of the ß-lactam drugs was a key factor to treatment potency, even though this is usually used to reject treatment that exclusively uses these drugs. Our study shows that spontaneous resistance rates of component antibiotics could be used as a guiding principle for sequential treatments and could improve the potency of sequential protocols.” This study has been published as part of ‘Evolutionary Medicine: A Special Issue’ from eLife. To view the Special Issue, visit https://elifesciences.org/collections/8d9426aa/evolutionary-medicine-a-special-issue. Reference: “High potency of sequential therapy with only ß-lactam antibiotics” by Aditi Batra, Roderich Roemhild, Emilie Rousseau, Sören Franzenburg, Stefan Niemann and Hinrich Schulenburg, 28 July 2021, eLife. DOI: 10.7554/eLife.68876

DVDV1551RTWW78V